Lumida
/AIRS
⌘K
AirSculpt Technologies Inc

AirSculpt Technologies Inc

AIRS
$4.45USD+6.97%+0.29 today

MARKET CAP

313.9M

P/E (TTM)

FWD P/E

DAY RANGE

$4 – $5

52W RANGE

$2
$12

AI Summary

Stalk
StalkMedium

In Stage 2 Advancing, AIRS retains a medium-term bullish bias underpinned by higher highs/lows and support at the rising 50 DMA, but short-term timing is neutral as price pulls back into the 9/21/50 EMA zone. Execution should be deferred around this support range, seeking evidence of acceptance before committing. Primary risk is a decisive break below the 50 DMA and prior higher-low, which would invalidate the bullish outlook.

  • GLP-1 meds could grow patient base from 5M to 25M by 2030, with 63% intent (~19M patients).
  • Q1 revenue $39.4M (+19% sequential; flat YoY) with same-center sales up 1%.
  • Negative earnings yield and significant revisions signal underlying operational weakness.
Full analysis →
Insider Trades8 trades
DateSideTickerInsiderRoleSharesPriceMkt Cap52W High52W LowValue% ChgRuleAI View
Mar 18, 2026SellAIRSYogesh JashnaniChief Executive Officer38,379$2.79$313.9M-62.92%+194.70%$107.1K-7.73%Stalk
Feb 3, 2026SellAIRSYogesh JashnaniChief Executive Officer24,217$2.58$313.9M-62.92%+194.70%$62.5K-4.65%Stalk
May 19, 2025BuyAIRSAaron RollinsExecutive Chairman2,118$3.60$313.9M-62.92%+194.70%$7.6K+0.01%Stalk
May 7, 2025BuyAIRSYogesh JashnaniChief Executive Officer7,000$2.65$313.9M-62.92%+194.70%$18.5K+1.53%Stalk
Nov 13, 2024SellAIRSDennis DeanInterim CEO and CFO54,607$6.94$313.9M-62.92%+194.70%$378.9K-2.92%Stalk
Nov 13, 2024SellAIRSAaron RollinsExecutive Chairman109,213$6.94$313.9M-62.92%+194.70%$757.7K-0.24%Stalk
Mar 14, 2024SellAIRSTodd MagazinePresident and CEO15,509$5.93$313.9M-62.92%+194.70%$92.0K-5.60%Stalk
Jan 30, 2024SellAIRSTodd MagazinePresident and CEO24,796$7.63$313.9M-62.92%+194.70%$189.2K-8.22%Stalk